Clinical Trials Logo

Blast Crisis clinical trials

View clinical trials related to Blast Crisis.

Filter by:

NCT ID: NCT00012376 Completed - Clinical trials for Chronic Myelomonocytic Leukemia

Chemotherapy Plus Sargramostim in Treating Patients With Refractory Myeloid Cancer

Start date: March 2001
Phase: Phase 1
Study type: Interventional

Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Colony-stimulating factors such as sargramostim may increase the number of immune cells found in bone marrow or peripheral blood and may help a person's immune system recover from the side effects of chemotherapy. Phase I trial to study the effectiveness of bryostatin 1 combined with sargramostim in treating patients who have refractory myeloid cancer

NCT ID: NCT00006475 Completed - Leukemia Clinical Trials

STI571 in Treating Patients With Chronic Myelogenous Leukemia in Blast Crisis

Start date: September 2000
Phase: Phase 2
Study type: Interventional

RATIONALE: STI571 may interfere with the growth of cancer cells and may be an effective treatment for leukemia. PURPOSE: Phase II trial to study the effectiveness of STI571 in treating patients who have chronic myelogenous leukemia in blast crisis.

NCT ID: NCT00006213 Completed - Clinical trials for Recurrent Adult Acute Myeloid Leukemia

BMS-214662 in Treating Patients With Acute Leukemia, Myelodysplastic Syndrome, or Chronic Myeloid Leukemia

Start date: April 2000
Phase: Phase 1
Study type: Interventional

Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Phase I trial to study the effectiveness of BMS-214662 in treating patients who have acute leukemia, myelodysplastic syndrome, or chronic myeloid leukemia in blast phase

NCT ID: NCT00005064 Completed - Clinical trials for Recurrent Adult Acute Myeloid Leukemia

PS-341 in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myeloid Leukemia in Blast Phase, or Myelodysplastic Syndrome

Start date: February 2000
Phase: Phase 1
Study type: Interventional

Phase I trial to study the effectiveness of PS-341 in treating patients who have refractory or relapsed acute myeloid leukemia, acute lymphoblastic leukemia, chronic myeloid leukemia in blast phase, or myelodysplastic syndrome. PS-341 may stop the growth of cancer cells by blocking the enzymes necessary for cancer cell growth

NCT ID: NCT00003997 Completed - Leukemia Clinical Trials

6-Hydroxymethylacylfulvene in Treating Patients With Refractory Myelodysplastic Syndrome, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, or Blastic Phase Chronic Myelogenous Leukemia

Start date: July 1999
Phase: Phase 1
Study type: Interventional

Phase I trial to study the effectiveness of 6-hydroxymethylacylfulvene in treating patients who have refractory myelodysplastic syndrome, acute myeloid leukemia, acute lymphocytic leukemia, or blastic phase chronic myelogenous leukemia. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die.

NCT ID: NCT00003735 Completed - Leukemia Clinical Trials

Chemotherapy in Treating Children With Relapsed Acute Leukemia, Acute Myeloid Leukemia, or Blastic Phase Chronic Myelogenous Leukemia

Start date: December 1998
Phase: Phase 2
Study type: Interventional

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of topotecan in treating children who have relapsed acute leukemia, acute myeloid leukemia, or blast phase chronic myelogenous leukemia.